Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC

Daniele Biacchi, Fabio Accarpio, Luca Ansaloni, Antonio Macrì, Antonio Ciardi, Orietta Federici, Alessandra Spagnoli, Davide Cavaliere, Marco Vaira, Paolo Sapienza, Paolo Sammartino

Research output: Contribution to journalArticle

Abstract

Background: Whether patients with advanced tubo-ovarian high-grade serous cancer (HGSC) fare better after upfront debulking surgery (UDS) or neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) remains controversial. Methods: We studied patients with HGSC who underwent UDS or NACT-IDS between July 2000 and December 2015, with peritonectomy procedures combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Clinical reports were included peritoneal cancer index (PCI), NACT responses, surgical complexity score (SCS), completeness of cytoreduction (CC), complete follow-up with timing, site, and treatment of recurrence. Outcome measures were morbidity, progression-free survival (PFS), PFS2, and overall survival during a mean 5-year follow-up. Results: A total of 34 patients (23.6%) underwent UDS and 110 (76.4%) NACT-IDS both combined with HIPEC. At a median 66.3-month follow-up, patients who underwent UDS or NACT-IDS had similar outcomes. NACT subgroup responses correlated with PCI, SCS, morbidity, and CC. Patients who underwent UDS had lower recurrence rates than those who responded partly or poorly to NACT (PFS, P <.04; PFS2, P <.01). Despite HIPEC, the peritoneal disease recurred in 42.5% of the overall patients. Conclusion: In patients with primary HGSC who undergo UDS or NACT-IDS, despite similar outcomes, peritonectomy procedures combined with HIPEC seem unable to prevent peritoneal recurrence.

Original languageEnglish
Pages (from-to)1208-1219
Number of pages12
JournalJournal of Surgical Oncology
Volume120
Issue number7
DOIs
Publication statusPublished - Dec 1 2019

Keywords

  • HIPEC
  • interval debulking surgery
  • neoadjuvant chemotherapy
  • ovarian high-grade serous carcinoma
  • upfront debulking surgery

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC'. Together they form a unique fingerprint.

  • Cite this

    Biacchi, D., Accarpio, F., Ansaloni, L., Macrì, A., Ciardi, A., Federici, O., Spagnoli, A., Cavaliere, D., Vaira, M., Sapienza, P., & Sammartino, P. (2019). Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC. Journal of Surgical Oncology, 120(7), 1208-1219. https://doi.org/10.1002/jso.25703